Frontlight ResearchEarly access
Triple-negative breast cancer trials in China
133 trials · From ClinicalTrials.gov, checked 15 November 2026. Ask the study team whether a trial fits you.
- Phase 1/2Not yet taking people in ChinaThe Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.
- Where
- Hangzhou
- Age
- 18 years to 70 years
- People
- 58
- Run by
- Zhejiang Cancer Hospital
See details and how to joinNCT06140576 - No phaseTaking people99mTc-MY6349 SPECT/CT Imaging in Trop2-positive Triple-negative Breast Cancer
- Where
- Beijing
- Age
- 18 years to 80 years
- People
- 30
- Run by
- Peking Union Medical College Hospital
See details and how to joinNCT06104085 - Phase 2Taking peopleStudy of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
- Where
- Chengdu
- Age
- 18 years to 75 years
- People
- 35
- Run by
- West China Hospital
See details and how to joinNCT05447702 - Phase 2Taking peopleA Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC
- Where
- Guandong
- Age
- 18 years to 80 years
- People
- 460
- Run by
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT04501523 - No phaseTaking peopleEstrogen Receptor (ER) PET/CT Imaging in Breast Cancer
- Where
- Wuhan
- Age
- 18 years and over
- People
- 80
- Run by
- Tongji Hospital
See details and how to joinNCT05541367 - Phase 4Taking peopleAlbumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer
- Where
- Changchun, Dalian, Harbin, Panjin, Shenyang
- Age
- 18 years to 70 years
- People
- 110
- Run by
- Shengjing Hospital
See details and how to joinNCT04136782 - Phase 3Taking peopleTreatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT
- Where
- Shenyang
- Age
- 18 years to 70 years
- People
- 1,498
- Run by
- Shengjing Hospital
See details and how to joinNCT04137653 - Phase 2Taking peopleAdjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy
- Where
- Beijing
- Age
- 18 years to 75 years
- People
- 286
- Run by
- Chinese Academy of Medical Sciences
See details and how to joinNCT04437160